Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy

This letter reports that the #SUMOylation inhibitor TAK‑981 downregulates #MYC, induces #apoptosis, and enhances CD19 CAR‑T efficacy in #BurkittsLymphoma, highlighting SUMOylation inhibition as a promising adjunct strategy.

#OpenAccess in #STTT: doi.org/10.1038/s413...

I wish I had made my make-a-wish something like “can I put this off until I need it when I’m an adult like a mafia favor?” Instead of swimming with the dolphins.

It would come in handy right now.

#MakeAWish #Survivor #LongTermIllness #BurkittsLymphoma #ChildhoodCancer

#SUMOylation inhibitor TAK-981 suppresses #BurkittsLymphoma (BL) and enhances #CD19 #CARTcell therapy by promoting Th2 polarization and boosting #cytotoxicity, highlighting the potential of SUMOylation blockade to overcome refractory BL.

#OpenAccess #STTT: doi.org/10.1038/s413...

This Wednesday at 9pm IST airing on TG4 in Gaeilge @tg4.bsky.social!

Tune in to learn about the life and work of Irish surgeon #DenisBurkitt and #TCDMedSchool alumn who discovered a rare form of cancer, #BurkittsLymphoma: